Results 221 to 230 of about 225,763 (291)

Development of Acute Coronary Syndrome and Progression of Coronary Artery Disease. A Serial Clinical-angiographic Analysis.

, 2000
Shigeyuki Nishimura, Kenichi Katoh
openalex   +2 more sources

Lower NT‐proBNP plasma concentrations in Pacific peoples with heart failure

ESC Heart Failure, EarlyView.
NT‐proBNP plasma concentrations were measured in participants of two NZ HF cohorts and were significantly lower in Pacific peoples and Māori compared with NZ Europeans. After accounting for age, sex, BMI, eGFR, LVEF and presence of AF, NT‐proBNP plasma concentrations remained significantly lower for Pacific peoples, but not for Māori.
Andree G. Pearson, John F. Pearson, Lynley K. Lewis, Allamanda Fa'atoese, Katrina K. Poppe, Chris Pemberton, Gerry Devlin, Mayanna Lund, A. Mark Richards, Richard Troughton, Robert N. Doughty   +10 more
wiley   +1 more source

Effect of Premature Acute Coronary Syndrome on Ocular Hemodynamics. [PDF]

Int J Med Sci
Wang JL, Wu LT, Wang YL.
europepmc   +1 more source

Hypertensive Heart Disease or Acute Coronary Syndrome?

, 2000
D Felmeden, G Y H Lip
openalex   +1 more source

Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety. [PDF]

Medicines (Basel)
Bahouth F, Chutko B, Sholy H, Hassanain S, Zaid G, Radzishevsky E, Fahmwai I, Hamoud M, Samnia N, Khoury J, Dobrecky-Mery I.   +10 more
europepmc   +1 more source

Obesity and Acute Coronary Syndromes

Hellenic Journal of Cardiology, 2016
openaire   +4 more sources

Pre‐admission beta‐blocker therapy and outcomes in cardiogenic shock: Insights from the Altshock‐2 Registry

ESC Heart Failure, EarlyView.
Among 668 with cardiogenic shock included in the multicentre prospective Altshock‐2 registry, 299 patients (44.8%) received pre‐admission beta‐blocker therapy. Previous beta‐blocker therapy influenced the early hemodynamic response to vasoactive drugs, but it was not associated with in‐hospital mortality.
Matteo Pagnesi, Mauro Riccardi, Alice Sacco, Giovanni Tavecchia, Giovanna Viola, Simone Frea, Martina Briani, Letizia Fausta Bertoldi, Maurizio Bertaina, Luciano Potena, Serafina Valente, Marco Marini, Gaetano Maria De Ferrari, Nicoletta D'Ettore, Astrid Cardinale, Rita Camporotondo, Matteo Rota, Guido Tavazzi, Nuccia Morici, Federico Pappalardo, Marco Metra, on behalf of the Altshock‐2 investigators   +21 more
wiley   +1 more source

Recent progress in metabolomic analysis of acute coronary syndrome: a narrative review. [PDF]

Cardiovasc Diagn Ther
Liu J, Li T, Qi X, He C.
europepmc   +1 more source

Smoking Cessation Strategies After Acute Coronary Syndrome. [PDF]

J Clin Med
Nazir A, Shetty Ujjar S, Seddiki MO, Jheinga M, Fan L.   +4 more
europepmc   +1 more source

METAB‐HTX: prospective, longitudinal cohort study evaluating cardiac and systemic metabolism after heart transplantation

ESC Heart Failure, EarlyView.
The METAB‐HTX trial is a prospective cohort study, evaluating cardiac and systemic metabolism among heart transplant recipients. Myocardial function, energetic and metabolism, allograft vasculopathy, allograft rejection, glucometabolism, lipometabolism, liver‐ and kidney function, leucocyte signatures and thromboinflammation will be evaluated ...
Amin Polzin, Daniel Scheiber, Fabian Voss, Jean Haurand, Elric Zweck, Daniel Oehler, Oliver Maier, Mareike Cramer, Maximilian Spieker, Constanze Moos, Ursala Tokhi, David Naguib, Philipp Mourikis, Marcel Benkhoff, Robert Wagner, Michael Roden, Heinz‐Peter Schultheiss, Sascha Dietrich, Hug Aubin, Udo Boeken, Artur Lichtenberg, Malte Kelm   +21 more
wiley   +1 more source